Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamal Majidpoor

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 25, 2023
The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockadeSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Pathology, Research and Practice|June 2, 2023
The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4Sasan Parvini, Jamal Majidpoor, Keywan Mortezaee
Drug Delivery and Translational Research|June 1, 2023
Extracellular vesicle-based drug delivery in cancer immunotherapySajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2023
Liquid biopsy in colorectal cancerSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology|July 17, 2023
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - UpdatedZana Karami, Keywan Mortezaee, Jamal Majidpoor
Life Sciences|October 29, 2022
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumorsSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 3, 2023
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapyKeywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 28, 2022
Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategiesKeywan Mortezaee, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 28, 2022
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapyElnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, et al.
Journal of Biochemical and Molecular Toxicology|August 31, 2021
The current knowledge concerning solid cancer and therapyMasoud Najafi, Jamal Majidpoor, Heidar Toolee, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 25, 2023
The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockadeSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Pathology, Research and Practice|June 2, 2023
The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4Sasan Parvini, Jamal Majidpoor, Keywan Mortezaee
Drug Delivery and Translational Research|June 1, 2023
Extracellular vesicle-based drug delivery in cancer immunotherapySajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2023
Liquid biopsy in colorectal cancerSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology|July 17, 2023
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - UpdatedZana Karami, Keywan Mortezaee, Jamal Majidpoor
Life Sciences|October 29, 2022
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumorsSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 3, 2023
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapyKeywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 28, 2022
Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategiesKeywan Mortezaee, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 28, 2022
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapyElnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, et al.
Journal of Biochemical and Molecular Toxicology|August 31, 2021
The current knowledge concerning solid cancer and therapyMasoud Najafi, Jamal Majidpoor, Heidar Toolee, et al.
Pageof 8